Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 14/20 | 0.65 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17881884 | 0.79 | RIPK1 (1.00) | RIPK1HCRTR2 | |
| SCHEMBL30054833 | 0.79 | RIPK1 (1.00) | RIPK1HCRTR2 | |
| SCHEMBL20710309 | 0.77 | RIPK1 (0.50) | RIPK1L3MBTL1 | |
| SCHEMBL20710310 | 0.73 | RIPK1 (0.63) | RIPK1L3MBTL1 | |
| SCHEMBL17881980 | 0.73 | RIPK1 (0.63) | RIPK1L3MBTL1 | |
| SCHEMBL20710319 | 0.73 | RIPK1 (0.63) | RIPK1L3MBTL1 | |
| SCHEMBL17881962 | 0.63 | RIPK1 (0.67) | RIPK1 | |
| SCHEMBL22066320 | 0.61 | RIPK1 (0.46) | RIPK1HCRTR2L3MBTL1 | |
| SCHEMBL22608919 | 0.61 | RIPK1 (0.51) | RIPK1HCRTR2 | |
| SCHEMBL17881960 | 0.61 | RIPK1 (0.71) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10555920-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-11 | — | — | US | disclosed |
| US-20190038578-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038578-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885HCRTR2 3813/4885L3MBTL1 3530/4885 |
| US-10555920-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885HCRTR2 3813/4885L3MBTL1 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.